subperiosteal implants
Status of the Hydroxyapatite-Coated Unilateral Subperiosteal Implant Using Direct Bone Impressions
- 18 January 1992
- Posted by: anjaform
- Category: Biomaterials
R. K. Stobaugh
Full text link: https://pubmed.ncbi.nlm.nih.gov/1310662/
Status of the Hydroxyapatite-Coated Unilateral Subperiosteal Implant Using Direct Bone Impressions
1. Scientific Reference
- Study title: Status of the hydroxyapatite-coated unilateral subperiosteal implant using direct bone impressions
- Author: R. K. Stobaugh
- Scientific journal: Not specified in the information provided.
- Year of publication: Not specified in the information provided.
- DOI: Not specified in the information provided.
- PMID: 1310662
2. Scientific Background
This publication addresses a specific approach to implant rehabilitation: the unilateral subperiosteal implant fabricated using direct bone impressions and incorporating a hydroxyapatite (HA)-coated framework. Within this context, particular attention is given to the relationship between the implant framework and the surrounding osseous and soft tissues.
The paper considers HA coating as a potential development in the evolution of established subperiosteal implant systems, with particular emphasis on tissue adaptation and compatibility. Its clinical scope extends beyond the coating itself, as the available abstract indicates that patient indications, technical considerations, commonly encountered complications, and representative clinical cases are also discussed.
The information provided, however, does not establish how this approach compares with other forms of implant rehabilitation. No quantitative comparison with alternative implant designs, surgical techniques, or treatment strategies is reported in the available abstract.
3. Study Objective
The primary purpose of the publication is to discuss the clinical status and potential value of the hydroxyapatite-coated unilateral subperiosteal implant when used for specifically selected indications.
The paper also examines the proposed contribution of the HA-coated framework to its relationship with bone and soft tissues while addressing relevant clinical aspects, including indications, procedural considerations, complications, and representative cases. No secondary objective or formal comparative hypothesis is specified in the information provided.
4. Methodology
The available abstract does not provide sufficient methodological information to classify the publication definitively as a prospective, retrospective, controlled, or comparative clinical study. It reports a discussion of indications, techniques, common complications, and typical clinical cases, suggesting a predominantly descriptive and clinically oriented publication.
The number of patients, number of implants, patient selection criteria, characteristics of the treated population, duration of follow-up, outcome measures, and detailed methodology for obtaining direct bone impressions are not specified in the available information.
Similarly, no control group, statistical analysis, or predefined quantitative endpoint is reported in the abstract. A more precise assessment of the study design would therefore require access to methodological information beyond that provided here.
5. Main Results
The publication presents the HA-coated unilateral subperiosteal implant as a clinically predictable and successful system when used for appropriately selected indications. The potential contribution attributed to hydroxyapatite primarily concerns the biological relationship between the framework and the surrounding tissues, with osseous and soft-tissue adaptation and compatibility described as appearing to benefit from the HA coating.
On this basis, the author considers hydroxyapatite coating a potential step in the further development of subperiosteal implant systems that had already demonstrated clinical utility.
The strength of this conclusion cannot be quantified from the abstract alone. No implant survival rate, success rate, complication frequency, number of failures, comparative outcome, or other numerical endpoint is provided. Consequently, the available evidence does not allow the magnitude of any clinical advantage associated with the HA coating to be determined.
6. Clinical Analysis
The principal clinical interest of this publication lies in combining a subperiosteal implant framework with a surface modification intended to influence its relationship with the surrounding biological environment. Rather than focusing exclusively on implant geometry, the paper highlights the potential importance of the interface between the framework, bone, and soft tissues.
An equally important aspect is the emphasis placed on appropriate indication. The favorable assessment of the implant system is explicitly linked to its use in specifically indicated situations. The findings should therefore not be interpreted as evidence supporting unrestricted use of HA-coated subperiosteal implants across all implant rehabilitation scenarios.
The inclusion of procedural considerations, complications, and representative cases gives the publication a practical clinical orientation. Nevertheless, the available information does not indicate how frequently complications occurred, how they were managed, or whether specific clinical or anatomical factors influenced the outcomes.
From an evidence-based perspective, the absence of reported sample size, follow-up duration, quantitative outcomes, and comparative data substantially limits the conclusions that can be drawn. The publication is therefore more appropriately interpreted as a clinical contribution concerning the potential role of HA coating in unilateral subperiosteal implant therapy than as definitive evidence of superior clinical performance.
7. Clinical Applications
Based strictly on the information provided, the findings are relevant to the use of unilateral subperiosteal implants in specifically selected clinical indications and to the application of hydroxyapatite coating as a means of potentially improving the interaction between the implant framework and surrounding osseous and soft tissues.
The publication may therefore be of interest to clinicians examining subperiosteal implant rehabilitation and implant frameworks produced using direct bone impressions.
However, the abstract does not define the anatomical characteristics, degree of bone deficiency, or other clinical features of the patients considered suitable for this treatment. It also provides no evidence allowing direct comparison with bone grafting, endosseous implants, or other reconstructive implant strategies.
8. Level of Evidence, Limitations, and Transparency
The level of evidence appears limited on the basis of the information available. The abstract describes clinical and technical considerations together with representative cases, but it does not provide sufficient information to identify a controlled comparative study design. A more precise methodological classification cannot therefore be established with confidence.
Important parameters required for critical appraisal are absent from the provided material, including sample size, number of implants, follow-up duration, predefined success criteria, quantitative outcomes, and a comparator. These omissions prevent a robust assessment of the reported predictability and clinical success of the system.
Detailed methodological limitations are not reported in the information provided. Likewise, no author conflicts of interest, financial relationships, or affiliations with an implant manufacturer are disclosed in the supplied material.
9. Key Study Points
- Study type: Clinically oriented descriptive publication with representative cases according to the abstract; exact methodological classification is not specified.
- Level of evidence: Limited and cannot be precisely determined from the information provided.
- Population or number of studies analyzed: Not specified in the information provided.
- Number of patients or implants: Not specified in the information provided.
- Follow-up duration: Not specified in the information provided.
- Primary outcome: No formal primary endpoint is specified; the publication addresses the clinical performance of the HA-coated unilateral subperiosteal implant and its relationship with surrounding tissues.
- Main finding: The implant system is presented as predictable and successful in specifically selected indications, while osseous and soft-tissue adaptation and compatibility appear to be enhanced by the HA-coated framework.
- Scientific conclusion: Hydroxyapatite coating is proposed as a potential further development of established subperiosteal implant systems.
- Potential limitations: Sample size, follow-up duration, quantitative outcomes, and detailed assessment criteria are not reported in the available abstract.
10. Scientific Impact
The scientific interest of this publication lies primarily in its consideration of surface modification as part of the evolution of subperiosteal implant therapy. By focusing on hydroxyapatite coating, the paper draws attention to the relationship between the implant framework and its surrounding biological environment rather than viewing subperiosteal rehabilitation solely from a mechanical or structural perspective.
The discussion of indications, technical aspects, complications, and clinical cases also provides a broader clinical perspective on this implant approach using direct bone impressions.
Its scientific impact should nevertheless be interpreted within the limits of the evidence available. The abstract does not quantify the proposed benefits of HA coating or establish superiority over an uncoated framework or another implant treatment. The publication is therefore best regarded as a clinical and technical contribution to the development of subperiosteal implant systems rather than as comparative evidence establishing the efficacy of HA coating.
11. Editorial Conclusion
Stobaugh’s publication highlights the use of hydroxyapatite coating in a unilateral subperiosteal implant fabricated using direct bone impressions, with particular attention to the implant framework’s relationship with bone and soft tissues. The emphasis on careful case indication is clinically relevant. However, the absence of quantitative outcomes, clearly defined methodological parameters, and follow-up data in the available abstract limits the strength of the conclusions. The paper should therefore be viewed as a clinically informative contribution to the development of subperiosteal implant therapy rather than definitive evidence of comparative effectiveness.
